Collaborations & Alliances

Multiply Labs, AstraZeneca Partner to Automate Cell Therapy Mfg. with Robotics

To evaluate the potential for applying GMP-ready robotic systems to commercial-scale cell therapy manufacturing.  

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Multiply Labs

Multiply Labs, a developer of autonomous manufacturing technology for advanced therapies, entered an agreement with AstraZeneca to evaluate the potential for applying GMP (Good Manufacturing Practices)-ready robotic systems to commercial-scale cell therapy manufacturing.   The collaboration will focus on end-to-end robotic automation of industry-standard instruments used in cell therapy production using Multiply Labs’ robotic biomanufacturing system. The goal is to enable scalable, high-throu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters